Categories AlphaGraphs, Health Care

Celgene stock takes a dive after major Bristol-Myers stakeholder opposes merger deal

It’s was a wild day for big pharma after Celgene Corp (CELG) slid at least 8% on early Thursday trade after one of the major shareholders of Bristol-Myers Squibb Co (BMY), Wellington Management, came out in opposition of the proposed $74-billion merger deal.

This has cast a shadow on what was touted as one of the biggest takeover deals of the pharmaceutical world.

In a letter that went public earlier on Thursday, Bristol-Myers Squibb Co said it was disappointed at the opposition of the institutional investor. But the company insisted it would try to move ahead as planned.

Wellington Management earns almost 8% of the BMY stock. The investor voiced concerns about the risk and expenses surrounding the deal.

Despite the fact that other investors could follow suit, Wall Street estimates that the deal would go through.

In its letter, BMY also stressed that the merger was the ideal path forward.

 

THE MAMMOTH DEAL

In the first week of 2019, Bristol-Myers announced the acquisition of its peer Celgene in a $74-billion cash-and-stock deal — where Celgene shareholders will receive 1 BMY share and $50 in cash for each share of Celgene. Shares of Celgene then jumped after the announcement, while Bristol-Myers Squibb stock plunged.

If the deal goes through, BMS shareholders will have 69% of the ownership and Celgene shareholders will have the rest 31%.

Celgene shareholders would also receive one tradeable Contingent Value Right (CVR) for each share of Celgene. This will entitle them to receive a payment if future regulatory milestones are achieved. The combined mammoth firm is said to have six expected near-term product launches.

The deal is expected to be more than 40% accretive to Bristol-Myers Squibb’s EPS on a standalone basis in the first full year following the close of the transaction. Bristol-Myers Squibb then said it looks to realize run-rate cost synergies of approximately $2.5 billion by 2022. It also added that more than $45 billion of free cash flow is expected to be generated over the first three full years after the deal is closed.

 

CELGENE, UPS AND DOWN

A month ago, Celgene posted its fourth-quarter results, where it swung to a profit from last year’s loss. This was mainly due to lower research and development costs as well as a fall in acquisition-related charges and restructuring.

Celgene fourth quarter 2018 earnings snapshot
Celgene Q4 2018 Earnings Infographic

While the results beat estimates, it also gave a healthy FY2019 outlook that came above the market consensus. Adjusted earnings grew 20% in the quarter, while total revenue jumped 16%.

Celgene had then said that it sees FY2019 total revenue between $17 billion and $17.2 billion, while the expected earningswere at $8.40-9.08 per share. Adjusted earnings was then touted to be $10.60-10.80 per share.

 

Earnings Calendar: Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

United Parcel Service (UPS) seems on track to regain lost strength

Cargo giant United Parcel Service, Inc. (NYSE: UPS) ended fiscal 2023 on a weak note, reporting lower revenues and profit for the fourth quarter. The company experienced a slowdown post-pandemic

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Comments

  1. Pingback: Lincoln Georgis
  2. Pingback: Reba Fleurantin
  3. Pingback: Lila Lovely BBW
  4. Pingback: sleep lotion
  5. Pingback: Click Here
  6. Pingback: Click Here
  7. Pingback: Click Here
  8. Pingback: Click Here
  9. Pingback: Click Here
  10. Pingback: Click Here
  11. Pingback: Click Here
  12. Pingback: Click Here
  13. Pingback: Click Here
  14. Pingback: Click Here
  15. Pingback: Click Here
  16. Pingback: Click Here
  17. Pingback: Click Here
  18. Pingback: Click Here
  19. Pingback: Click Here
  20. Pingback: Click Here
  21. Pingback: Click Here
  22. Pingback: Click Here
  23. Pingback: Click Here
  24. Pingback: spaceros
  25. Pingback: Click Here
  26. Pingback: Click Here
  27. Pingback: Click Here
  28. Pingback: Click Here
  29. Pingback: Click Here
  30. Pingback: Click Here
  31. Pingback: Click Here
  32. Pingback: Click Here
  33. Pingback: Click Here
  34. Pingback: Click Here
  35. Pingback: Click Here
  36. Pingback: Click Here
  37. Pingback: Click Here
  38. Pingback: Click Here
  39. Pingback: Click Here
  40. Pingback: Click Here
  41. Pingback: Click Here
  42. Pingback: Click Here
  43. Pingback: Click Here
  44. Pingback: Click Here
  45. Pingback: Click Here
  46. Pingback: Click Here
  47. Pingback: Click Here
  48. Pingback: Click Here
  49. Pingback: Click Here
  50. Pingback: Click Here
  51. Pingback: Click Here
  52. Pingback: Click Here
  53. Pingback: Click Here
  54. Pingback: Click Here
  55. Pingback: Click Here
  56. Pingback: earn karo
  57. Pingback: Click Here
  58. Pingback: Click Here
  59. Pingback: Click Here
  60. Pingback: Click Here
  61. Pingback: Click Here
  62. Pingback: Click Here
  63. Pingback: Click Here
  64. Pingback: Click Here
  65. Pingback: Click Here
  66. Pingback: Click Here
  67. Pingback: Click Here
  68. Pingback: premium-domains
  69. Pingback: domain-broker
  70. Pingback: business blogs
  71. Pingback: Google reviews
  72. Pingback: 2023 Books
  73. Pingback: birth records
  74. Pingback: funeral director
  75. Pingback: deceased
  76. Pingback: Cultural diversity
  77. Pingback: Academic Advising
  78. Pingback: Pharmacy's Diploma
  79. Pingback: Water Bath
  80. Pingback: Sedation dentistry
  81. Pingback: Radiography
  82. Pingback: distance education
  83. Pingback: ?????? ???????
  84. Pingback: Career Counseling
  85. Pingback: Magnetic stirrers
  86. Pingback: Gum Disease
  87. Pingback: Fiverr Earn
  88. Pingback: Fiverr Earn
  89. Pingback: fiverrearn.com
  90. Pingback: fiverrearn.com
  91. Pingback: Freight Broker
  92. Pingback: flatbed broker
  93. Pingback: fiverrearn.com
  94. Pingback: SEO in Jordan
  95. Pingback: crypto news
  96. Pingback: 18k gold plated
  97. Pingback: best budget phones
  98. Pingback: future university
  99. Pingback: french bulldogs
  100. Pingback: blue frenchie
  101. Pingback: fue
  102. Pingback: lean six sigma
  103. Pingback: Warranty
  104. Pingback: Piano service
  105. Pingback: FUE
  106. Pingback: FUE
  107. Pingback: Media
  108. Pingback: Speaker
  109. Pingback: FiverrEarn
  110. Pingback: pupuk anorganik
  111. Pingback: pupuk organik cair
  112. Pingback: partners
  113. Pingback: Governance
  114. Pingback: french bulldog
  115. Pingback: FiverrEarn
  116. Pingback: FiverrEarn
  117. Pingback: live sex cams
  118. Pingback: FiverrEarn
  119. Pingback: FiverrEarn
  120. Pingback: FiverrEarn
  121. Pingback: FiverrEarn
  122. Pingback: FiverrEarn
  123. Pingback: FiverrEarn
  124. Pingback: FiverrEarn
  125. Pingback: FiverrEarn
  126. Pingback: filmebi qartulad
  127. Pingback: wix seo specialist
  128. Pingback: shopping cart
  129. Pingback: personalized
  130. Pingback: Kuliah Termurah
  131. Pingback: FiverrEarn
  132. Pingback: cheap sex cams
  133. Pingback: fullersears.com
  134. Pingback: fullersears.com
  135. Pingback: canine probiotics
  136. Pingback: live sex cams
  137. Pingback: frt trigger
  138. Pingback: 늑대닷컴
  139. Pingback: Judi slot online
  140. Pingback: One Peace AMV
  141. Pingback: One Peace AMV
  142. Pingback: superslot
  143. Pingback: allgame
  144. Pingback: 918kiss
  145. Pingback: หวย24
  146. Pingback: pg slot
  147. Pingback: AI Lawyer
  148. Pingback: itsMasum.Com
  149. Pingback: itsMasum.Com
  150. Pingback: itsMasum.Com
  151. Pingback: nangs sydney
Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top